Matthew Angel - 12 Jan 2023 Form 4 Insider Report for Eterna Therapeutics Inc. (ERNA)

Reporting relationship: President and CEO, Director
Issuer ticker: ERNA
Reported as of: 12 Jan 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 13 Jan 2023, 18:30:32 UTC
Prior SEC filing: 03 Aug 2022
Next SEC filing: 06 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Matthew Angel

Key filing fact

Matthew Angel filed Form 4 for Eterna Therapeutics Inc. (ERNA) on 13 Jan 2023.

Key facts

This page summarizes Matthew Angel's Form 4 filing for Eterna Therapeutics Inc. (ERNA).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 13 Jan 2023, 18:30.

Change

Previous filing in this sequence was filed on 03 Aug 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ERNA transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +132,003
Change %
Price: $0.000000
Shares after: 132,003
Date: 12 Jan 2023
Ownership: Direct
Underlying class: Common Stock, par value $0.005 per share
Underlying amount: 132,003
Exercise price: $4.84
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The stock options vests and becomes exercisable over three years (subject to continued service), with 110,043 of the shares vesting on the grant date, and the remaining shares vesting in 36 substantially equal monthly tranches on the first day of each month thereafter.